Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05897021 · ClinicalTrials.gov registry record · NA

Expressive Writing on Minority Stressors Among Sexual Minority Veterans

A NA study of Anxiety and Depressive Symptoms, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
85
Enrollment target
1
Study location

NCT05897021: Recruiting NA study of Anxiety and Depressive Symptoms, sponsored by VA Office of Research and Development.

NCT05897021 is a NA study of Anxiety and Depressive Symptoms that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 85 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05897021, a NA study of Anxiety and Depressive Symptoms, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
85 participants
Enrollment target
1
Study location

Study Summary

Sexual minority stressors (e.g., sexual minority identity-based discrimination) contribute to greater risk for and severity of depression, anxiety, substance use disorders and suicide among sexual minority Veterans. However, no brief, scalable, one-on-one interventions targeting sexual minority stressor-related distress are available in Veterans Affairs (VA) for sexual minority Veterans. The proposed research will examine the feasibility, acceptability, and preliminary effectiveness of a brief, 3-session expressive writing intervention to target distress related to sexual minority stressor exposure among sexual minority Veterans. The results of this work will advance knowledge about a promising brief and easy to implement intervention focused on reducing depressive and anxiety symptoms among sexual minority Veterans. This proposal aligns with VA's and CSR\&D's commitment to providing equitable services to sexual minority Veterans and the aim of reducing health disparities among underserved Veteran groups.

Primary Outcome

Level of feasibility will be assessed by comparable percentage of treatment completion as found in a previous efficacy trial of Expressive Writing on Minority Stressors in a non-Veteran sample (Pachankis et al., 2021). The percentage of treatment completion will be comparable to percentage of treatment completion reported in a previous efficacy trial of EWMS with young adults (89%) (Pachankis et al., 2021).

Interventions

  • BEHAVIORAL Neutral Writing
  • BEHAVIORAL Expressive Writing on Minority Stressors

Study Locations (1)

Massachusetts

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2024-03-20
Est. Completion 2028-09-30
Phase NA
VA Office of Research and Development

1,668 total trials

What NCT05897021 shows while recruiting

NCT05897021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (81% lower).

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Neutral Writing is the first listed.

NCT05897021 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05897021 about?

NCT05897021 is a clinical study titled "Expressive Writing on Minority Stressors Among Sexual Minority Veterans". Sexual minority stressors (e.g., sexual minority identity-based discrimination) contribute to greater risk for and severity of depression, anxiety, substance use disorders and suicide among sexual minority Veterans. However, no brief, scalable, one-on-one interventions targeting sexual minority stre...

What is the current status of trial NCT05897021?

This trial is currently recruiting. It is a NA study. The enrollment target is 85 participants. The study started on 2024-03-20. Estimated completion is 2028-09-30.

What conditions does trial NCT05897021 study?

This clinical trial studies the following conditions: Anxiety, Depressive Symptoms.

What interventions are being tested in trial NCT05897021?

The interventions under investigation include: Neutral Writing (BEHAVIORAL), Expressive Writing on Minority Stressors (BEHAVIORAL).

Who is sponsoring clinical trial NCT05897021?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05897021 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05897021's enrollment target sits among peer trials

85 190th of 364 higher than 173 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05897021, the US trial registry maintained by the National Library of Medicine. NCT05897021 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.